Work

A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps3161

Authors: Charlotte Rose Lemech, Warren Lance Joubert, Andrew Ohyama Parsonson, Rui-Hua Xu, Rajiv Shinde, Prachi Bhave, Junli Xue, Yaling Huang, Xun Meng, Shu-Hui Liu

Institutions: Greenslopes Private Hospital, Macquarie University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Linear Clinical Research, Cabrini Hospital, Shanghai East Hospital, Multitude Therapeutics (United States)

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410822216

FWCI: 1.625

Cites:

Cited by: 3

Related to: 10